Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging

Nucl Med Commun. 2006 Dec;27(12):933-7. doi: 10.1097/01.mnm.0000243374.11260.5b.

Abstract

Background and aims: Functional pre-synaptic dopamine brain imaging is generally abnormal when parkinsonism is degenerative (such as in idiopathic Parkinson's disease) and normal in patients with non-degenerative movement disorder (such as essential tremor). However, some patients diagnosed as early Parkinson's disease have normal presynaptic dopamine imaging. Follow-up of patients with normal imaging should help determine whether such patients truly have degenerative parkinsonism (and therefore represent false negative imaging results), or emerge as cases of non-degenerative parkinsonism (and therefore represent initial clinical over-diagnosis of Parkinson's disease).

Methods and results: One hundred and fifty cases with normal I-FP-CIT SPECT undertaken during routine care over a 3-year period were reviewed 2.4 years (interquartile range, 2.2-3.1 years) after SPECT. Diagnosis after follow-up was non-degenerative parkinsonism or tremor in 146 (97%), who did not progress clinically, and degenerative parkinsonism in four (3%), in whom clinical progression was noted. Anti-Parkinson therapy was used in 36, and withdrawn in 27 with no deterioration in 25. Patients strictly fulfilling Brain Bank criteria (part 1) were more likely to undergo a trial of anti-Parkinson therapy (P < 0.05) but were no more likely to maintain or respond to anti-Parkinson therapy than those not fulfilling criteria.

Conclusion: The clinical profile and therapy response during follow-up of patients with normal presynaptic dopamine imaging supports the diagnosis of a non-degenerative movement disorder in nearly all cases.

Publication types

  • Clinical Trial

MeSH terms

  • Antiparkinson Agents / therapeutic use*
  • Brain / diagnostic imaging
  • Brain / metabolism
  • Dopamine Plasma Membrane Transport Proteins / metabolism
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care / methods*
  • Outcome Assessment, Health Care / statistics & numerical data
  • Parkinson Disease / diagnostic imaging*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / epidemiology
  • Parkinson Disease / metabolism
  • Radiopharmaceuticals / pharmacokinetics
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Tomography, Emission-Computed, Single-Photon / methods
  • Tomography, Emission-Computed, Single-Photon / statistics & numerical data
  • Treatment Outcome
  • Tropanes* / pharmacokinetics
  • United Kingdom / epidemiology

Substances

  • Antiparkinson Agents
  • Dopamine Plasma Membrane Transport Proteins
  • Radiopharmaceuticals
  • Tropanes
  • 2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane